-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III

Symposia: Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy Program: Oral and Poster Abstracts
Type: Poster
Monday, December 11, 2023: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

Jusuf Imeri1*, Paul Marcoux1*, Matthias Huyghe1*, Christophe Desterke, PhD2,3*, Daianne Fantacini4*, Frank Griscelli, PharmD, PhD1,5*, Dimas T. Covas, MD, PhD6,7,8, Lucas Edouardo Botelho de Souza9,10*, Annelise Bennaceur Griscelli, MD, PhD1,11,12* and Ali Turhan, MD, PhD13

1Inserm U1310, Villejuif, France
2Faculty of Medicine, University Paris Saclay, Le Kremlin Bicetre, France
3Inserm U1310, Villejuif, FRA
4Ribeirao Preto School of Medicine, Blood Center, RibeirãO Preto, BRA
5Center for iPSC Therapies, CITHERA, Evry Genopole, France
6Biotechnology Cluster of Ribeirao Preto, Butantan Institute, Ribeirao Preto, Brazil
7Faculdade De Medicina De Ribeirao Preto -USP, Ribeirao Preto, Brazil
8Department of Clinical Medicine, Division of Hematology, School of Medicine of Ribeirão Preto - University of São Paulo (FMRP-USP), Ribeirão Preto, Brazil
9Ribeirão Preto/Ribeirão Preto School of Medicine/University of São Paulo - Ribeirão Preto/SP, Brazil., Blood Center, Ribeirao Preto, Brazil
10Biotechnology Nucleus of Ribeirão Preto, Butantan Institute, Ribeirao Preto, Brazil
11Center for iPSC Therapies, Evry Genopole, France
12University Paris Saclay-Division of Hematology, 94805, Villejuif, FRA
13CITHERA, Center for iPSC Therapies, Evry, France

Pan Wang, Ph.D.1*, Xu Han, PhD1*, Kehan Ren1, Ermin Li, Ph.D.1*, Honghao Bi, PhD2, Inci Aydemir2* and Peng Ji, MD, PhD1

1Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL
2Northwestern University, Chicago, IL

Ivo Veletic, MD1*, Taghi Manshouri, PhD1*, Christopher D. Pacheco, BS1*, C. Cameron Yin, MD, PhD2, Ying Zhang, MD1*, Ping Li, PhD1*, Evan N. Cohen, PhD2*, Javier A. Gomez1*, Jared K. Burks, PhD1*, Srdan Verstovsek, MD, PhD1 and Zeev Estrov, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Shinobu Matsuura, PhD, DVM1, Siyang Long, MS2*, Iris Karkempetzaki2,3*, Aikaterini Karagianni, MS, PhD2,3*, Xiaosheng Yang, MS2*, Nasi Huang, MD2*, Yuchen Liu, PhD4*, Chao Zhang, MS, PhD4* and Katya Ravid, Dsc2

1Cardiovascular Section/Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA
2Whitaker Cardiovascular Institute, Boston University Chobanian and Avedisian School of Medicine, Boston, MA
3Department of Internal Medicine, University of Crete, School of Medicine, Heraklion, Greece
4Section of Computational Biomedicine/Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA

Fan He, PhD1, Tim Kong, MSc2, Shuyang Lin2*, Mary C. Fulbright2*, Angelo B. A. Laranjeira2*, Daniel A.C. Fisher2*, Maggie J Cox2*, Katrina Ashworth3*, Jorge Di Paola, MD3 and Stephen T. Oh, MD, PhD4

1Division of Hematology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
2Division of Hematology, Department of Medicine, Washington University School of Medicine, St Louis, MO
3Department of Pediatrics, Washington University School of Medicine, St Louis, MO
4Department of Medicine, Washington University School of Medicine, Saint Louis, MO

Yanjie Li1,2,3*, Hui Gao1,3*, Yahui Liu1,3,4*, Chunling Fu1,3,4*, Wen Ju3,4*, Kailin Xu1,5,6*, Jianlin Qiao, PhD1,3,7 and Lingyu Zeng1,3,4,8*

1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
2Laboratory Center of Diagnostics, Xuzhou Medical University, Xuzhou, China
3Key Laboratory of Bone Marrow Stem Cell, Xuzhou, China
4Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
5Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, China
6Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
7Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou City, Jiangsu Province, China
8College of Medical Technolog, Xuzhou Medical University, Xuzhou, China

Anitria Cotton, MBA, BS1*, Ryan Collinson2*, Lynne Wilson2*, Zi Yun Ng3*, Hun S Chuah3*, Michael F. Leahy, FRACP3, Rebecca Howman4*, Carolyn Grove2,4,5, Hasib Sidiqi6*, Malcolm Webb7*, Darren Boey2*, Olivia Ruhen2*, Michael Phillips8*, Matthew Linden2*, Kathy Fuller, PhD2*, Wendy N. Erber, MD PhD2,5, Ronald Hoffman, MD9, John D. Crispino, PhD, MBA1 and Belinda Guo2*

1Division of Experimental Hematology, St Jude Children's Research Hospital, Memphis, TN
2School of Biomedical Sciences, University of Western Australia, Crawley, Australia
3Royal Perth Hospital, Perth, Australia
4Sir Charles Gairdner Hospital, Crawley, Australia
5PathWest Laboratory Medicine, Nedlands, Australia
6Fiona Stanley Hospital, Murdoch, Australia
7Hollywood Private Hospital, Nedlands, Australia
8Centre for Medical Research, University of Western Australia, Crawley, Australia
9Icahn School of Medicine at Mount Sinai, New York

Joan How, MD1, Anna E. Marneth, PhD1,2, Baransel Kamaz, MD3*, Chulwoo J. Kim4*, Donna S. Neuberg, ScD5, Siyang Ren, MS5*, Mohammed Wazir6, Lachelle D. Weeks, MD, PhD7, Maximilian Stahl, MD8, Daniel J. DeAngelo9, R. Coleman Lindsley10, Marlise R. Luskin, MD7, Sahand Hormoz, PhD11* and Ann Mullally, MD1

1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA
2Department of Laboratory Medicine, Division Laboratory of Hematology, Radboud University Medical Center, Nijmegen, Netherlands
3Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
4Department of Medicine, Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
5Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
6Department of Medicine, Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA
7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
8Dana Farber Institute, Boston, MA
9Dana-Farber Cancer Institute, Boston, MA
10Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
11Harvard University, Boston, MA

Ranran Zhang, MD1,2*, Yashaswini Janardhanan3*, Rohit Haldar3*, Leanne Cooper3*, Sebastien Jaquelin, PhD1*, Jasmin Straube, PhD4*, Megan Bywater, PhD1,3* and Steven W Lane, MD, PhD3,5,6

1The University of Queensland, Brisbane, QLD, Australia
2Cancer Program, QIMR berghofer medical research Institute, Brisbane, Australia
3Cancer Program, QIMR berghofer medical research Institute, Brisbane, QLD, Australia
4Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
5Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
6School of Biomedical Sciences, The University of Queensland, Brisbane, Australia

Xiaoli Wang, MD, PhD1*, Andrew Davis1*, Xiaoping Su, PhD2*, Muharrem Muftuoglu, MD3, Cecile Krejsa, PhD4, John Mascarenhas, MD1*, Michael Andreeff, MD PhD5 and Ronald Hoffman, MD1

1Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
2Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
3Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Kartos Therapeutics and Telios Pharma, Redwood City, CA
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Blake Moses, PhD, Mike Dills*, Ashlyn Wheeler*, Radina Todorova*, Savanna Macaluso*, Tyler Damen, PhD*, Samuel Cadena, PhD*, Lorena Lerner, PhD*, Jasbir Seehra, PhD* and Jenn Lachey, PhD

Keros Therapeutics, Lexington, MA

Eduard Mas Marin, PhD, MSc, BSc, PharmD, BA1, Sabrina Mir, BS2*, Eli M Soyfer, MS3, Jane H Chen, BS4*, Jianhong C Heidmann, BS5*, Simran Bhardwaj6*, Gajalakshmi Ramanathan, PhD6* and Angela G. Fleischman, MD, PhD5

1University of California, Irvine, IRVINE, CA
2School of Medicine, University of California, Irvine, Irvine, CA
3Medicine, Biological Chemistry, University of California, Irvine, Irvine, CA
4University of California, Irvine, Irvine
5Division of Hematology/Oncology, University of California, Irvine, Irvine, CA
6University of California, Irvine, Irvine, CA

Danny Jeyaraju, PhD1*, Sheida Hayati2*, Jia Wang3*, Claire N Harrison4, Jean-Jacques Kiladjian, MD, PhD5, Christopher Hernandez3*, Patrick Brown3*, Daniel Lopes De Menezes, PhD6*, Anita K. Gandhi, PhD3 and Rajasekhar N.V.S. Suragani, PhD7

1Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ
2Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, NJ
3Bristol Myers Squibb, Princeton, NJ
4Guy’s and St. Thomas’ NHS Foundation Trust, London, ENG, United Kingdom
5Hopital Saint-Louis, Paris, France
6Bristol Myers Squibb, San Francisco, CA
7Hematology, Translational Medicine and Disease Team, Bristol Myers Squibb, Summit, NJ

Francesca Palandri, MD1*, Giulia Benevolo, MD2*, Elena Maria Elli, MD3*, Roberto Latagliata4*, Giuseppe Auteri, MD5,6*, Filippo Branzanti, MSc1*, Mario Tiribelli, MD7*, Francesco Cavazzini, MD8*, Alessia Tieghi, MD9*, Nicola Polverelli, MD10, Alessandra D'Addio, MD11*, Elisabetta Abruzzese, MD12, Federica Colombo, MD13*, Marta Venturi1,5*, Francesco Ramundo14,15*, Rikard Mullai, MD16*, Antonio Cuneo, MD17*, Benedetto Bruno, MD, PhD18, Michele Cavo, MD5,19*, Giuseppe Alberto Palumbo, MD20*, Florian H Heidel, MD21, Massimo Breccia22* and Valerio De Stefano, MD15,23*

1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy, Bologna, Italy
2University Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy, Torino, Italy
3Fondazione IRCCS, San Gerardo dei Tintori, Monza, Monza, Italy
4Hematology Unit, Ospedale Belcolle, Viterbo, Italy, Rome, ITA
5Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy, Bologna, Italy
6IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy, Bologna, ITA
7Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy
8Division of Hematology, University of Ferrara, Ferrara, Ferrara, ITA
9Department of Hematology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Reggio Emilia, ITA
10Unit of Blood Diseases and Stem Cells Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Brescia, Italy
11Division of Hematology, Onco-hematologic Department, AUSL della Romagna, Ravenna, Ravenna, ITA
12Division of Hematology, Ospedale S. Eugenio, Roma, Roma, Italy
13Hematology Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
14Hematology Division, Sapienza University, Policlinico Umberto I, Rome, Roma, Italy
15Institute of Hematology, Catholic University School of Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Roma, Italy
16Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Udine, Italy
17Division of Hematology, University of Ferrara, Ferrara, Ferrara, Italy
18Division of Hematology and Stem Cell Transplant Unit, University Hospital AOU Città della Salute e della Scienza, Torino, Italy
19Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Bologna, Italy
20Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, University of Catania, Catania, Catania, Italy
21Internal Medicine II, Hematology and Oncology, Friedrich-Schiller-University Medical Center, Jena, Germany, Greifswald, Germany
22Division of Cellular Biotechnologies and Hematology, University Sapienza, Roma, Roma, Italy
23Hematology Division, Sapienza University, Policlinico Umberto I, Rome, Rome, Italy

Mamta Garg, MD, MBBS, FRCP, FRCPath1*, Siddharth Agarwal, MBBS2* and Graham Asagba, MBBS FRCP FRCPath1*

1University Hospital Leicester, Leicester, United Kingdom
2Radiology, University of Nottingham, Nottigham, United Kingdom

Liqiang Zhang1*, Kathryn McGinnis, BS1*, Paul Gonzales, BS1*, Maggie Murray, BS1*, Emily Cluff, MS1*, MD Babu Mia2*, Christoph Schaniel, PhD3*, Joseph Mascarenhas, PhD1*, Alan M Miller, MD PhD4, Ronald Hoffman, MD5 and Stephen Gately, PhD1*

1Translational Drug Development (TD2), Scottsdale, AZ
2TISCH CANCER CENTER, Icahn School of Medicine at Mount Sinai, NEW YORK, NY
3The Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine At Mount Sinai, New York, NY
4Translational Drug Development (TD2), Erie, CO
5Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

Garima Pandey, PhD1, Lucia Mazzacurati, PhD1*, Nathan P. Horvat, MD1*, Tegan Rowsell, BS1*, Narmin E. Amin, MS1*, Guolin Zhang, PhD1*, Afua Adutwumwa Akuffo, PhD1*, Christelle M. Colin-Leitzinger, PhD1*, Eric B. Haura, MD1*, Andrew T. Kuykendall, MD1,2, PK Epling-Burnette, PharmD, PhD1* and Gary W. Reuther, PhD3

1Moffitt Cancer Center, Tampa, FL
2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
3H. Lee Moffitt Cancer Center, Tampa, FL

Gopila Gupta1*, May Chiu2, Eshrak Al-Shaibani3*, Maria Agustina Perusini, MD4, Josephine Lucero5, Daniela Zackova, MD6*, Ivana Jeziskova7*, Anezka Kvetkova7*, Tomas Jurcek7*, Jaeyoon John Kim8*, Danielle Pyne9*, Anthea Travas10*, Amirthagowri Ambalavanan10*, Jiri Mayer, Prof, MD11,12, Jessie Medeiros10, Sagi Abelson1,13* and Dennis Dong Hwan Kim, MD, PhD14,15,16,17,18

1University Health Network, Princess Margaret Cancer Centre, Toronto, Canada
2PRINCESS MARGARET CANCER CENTRE- UNIVERSITY HEALTH CENTRE, Christchurch, New Zealand
3Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
4Princess Margaret Cancer Centre / University Health Network, Toronto, ON, Canada
5Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
6University Hospital Brno and Masaryk University, Brno, CZE
7Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
8Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
9University Health Network, Toronto, ON, Canada
10University Health Network, Toronto, Canada
11Masaryk University and University Hospital Brno, Brno, Czech Republic
12Clinic of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
13Ontario Institute for Cancer Research, Toronto, Canada
14Hans Messner Allogenic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
15Faculty of Medicine, Department of Medicine, University of Toronto, Toronto, ON, Canada
16Hans Messner Allogenic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
17Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada
18Leukemia program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada

Hamza Celik*, Maryanne Covington*, Katherine Drake*, Kamna Katiyar*, Alex Margulis*, Amanda Smith*, Gaurang Trivedi*, Brittney Wass*, Guofeng Zhang, Nina Zolotarjova*, Sunkyu Kim* and Ricardo Macarrón

Incyte Research Institute, Wilmington, DE

Valentina Boldrini, MD1,2*, Paola Guglielmelli, MD, PhD2,3, Giada Rotunno2,3*, Chiara Maccari2,3*, Giacomo Coltro, MD2,3*, Giuseppe Gaetano Loscocco, MD2,3*, Francesco Mannelli, MD2,3*, Naseema Gangat, MBBS4, Ayalew Tefferi, MD4 and Alessandro M. Vannucchi2,3

1University of Florence, Florence, Italy
2CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
3Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
4Division of Hematology, Mayo Clinic, Rochester, MN

*signifies non-member of ASH